Report of Foreign Issuer (6-k)
July 16 2019 - 10:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2019
Commission File Number:
001-31368
SANOFI
(Translation of
registrants name into English)
54, rue La
Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by
Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
82-
In June and July 2019, Sanofi issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3, 99.4,
99.5 and 99.6 which are incorporated herein by reference.
Exhibit List
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated July 10, 2019: Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
|
|
|
Exhibit 99.2
|
|
Press release dated July 03, 2019: Sanofi : Libtayo
®
(cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
|
|
|
Exhibit 99.3
|
|
Press release dated June 28, 2019: Sanofi : CHMP recommends approval of Dupixent
®
(dupilumab) for
moderate-to-severe
atopic dermatitis in adolescents
|
|
|
Exhibit 99.4
|
|
Press release dated June 27, 2019: Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
|
|
|
Exhibit 99.5
|
|
Press release dated June 26, 2019: Sanofi : FDA approves Dupixent
®
(dupilumab) for chronic rhinosinusitis with nasal polyposis
|
|
|
Exhibit 99.6
|
|
Press release dated June 21, 2019: Sanofi and Regeneron announce positive topline Phase 2 results for
IL-33
antibody in asthma
|
2
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated July 10, 2019: Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
|
|
|
Exhibit 99.2
|
|
Press release dated July 03, 2019: Sanofi : Libtayo
®
(cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
|
|
|
Exhibit 99.3
|
|
Press release dated June 28, 2019: Sanofi : CHMP recommends approval of Dupixent
®
(dupilumab) for
moderate-to-severe
atopic dermatitis in adolescents
|
|
|
Exhibit 99.4
|
|
Press release dated June 27, 2019: Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
|
|
|
Exhibit 99.5
|
|
Press release dated June 26, 2019: Sanofi : FDA approves Dupixent
®
(dupilumab) for chronic rhinosinusitis with nasal polyposis
|
|
|
Exhibit 99.6
|
|
Press release dated June 21, 2019: Sanofi and Regeneron announce positive topline Phase 2 results for
IL-33
antibody in asthma
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Dated: July 16, 2019
|
|
|
|
|
|
SANOFI
|
|
|
|
|
|
By
|
|
/s/ Alexandra
Roger
|
|
|
|
|
Name:
|
|
Alexandra Roger
|
|
|
|
|
Title:
|
|
Head of Securities Law and Capital Markets
|
4
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Sep 2023 to Sep 2024